782
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Quinoxalin-2-carboxamides: synthesis and pharmacological evaluation as serotonin type-3 (5-HT3) receptor antagonists

, , &
Pages 610-615 | Received 12 Feb 2010, Accepted 20 Nov 2010, Published online: 11 Jan 2011
 

Abstract

A series of quinoxalin-2-carboxamides were designed as per the pharmacophoric requirements of 5-HT3 receptor antagonists and synthesized by condensing the carboxylic group of quinoxalin-2-carboxylic acid with various amines in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole. The structures of the synthesized compounds were confirmed by physical and spectroscopic data. The carboxamides were evaluated for their 5-HT3 receptor antagonisms in longitudinal muscle-myenteric plexus preparation from guinea pig ileum against 5-HT3 agonist, 2-methy-5-HT. All the synthesized compounds showed 5-HT3 receptor antagonism, (4-benzylpiperazin-1-yl)(quinoxalin-2-yl)methanone was the most potent compound among this series.

Acknowledgements

The authors thank the University Grants Commission (UGC), India, Birla Institute of Technology & Science (BITS), Pilani, India and SAIF, Panjab University, Chandigarh, India for providing financial support, laboratory and analytical facilities, respectively.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.